Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Misoprostol versus oxytocin for prevention of postpartum hemorrhage during cesarean delivery
IRCT20100429003833N2Phase 2Completed
- Sponsor
- Tabriz University of Medical Sciences
- Start
- Oct 2021
- Modality
- Recombinant Proteins and Enzymes, Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of misoprostol and oxytocin in postpartum hemorrhage (PPH) (3 arms), sponsored by Tabriz University of Medical Sciences. Primary endpoints: Bleeding volume during cesarean section and within 24 hours after surgery, Drug side effects and 1 more. Started Oct 2021; status: completed.
02
Drugs
misoprostoloxytocin
03
Conditions
postpartum hemorrhage (PPH)
Beyond the preview
Go deeper on IRCT20100429003833N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20100429003833N2.